Use of recombinant factor IX in subjects with haemophilia B undergoing surgery
暂无分享,去创建一个
K. Pasi | M. Ragni | G. White | S. Courter | K. Tubridy | P. Giangrande
[1] C. Kessler,et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2001, Blood.
[2] P. Collins,et al. Recombinant factor IX (BeneFix®) by adjusted continuous infusion: a study of stability, sterility and clinical experience , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[3] Rodgers,et al. Immunosuppressive effects of factor IX products: an in vitro study , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] J. Rouse,et al. Biochemical characterization of recombinant factor IX. , 1998, Seminars in hematology.
[5] P. Garzone,et al. Clinical evaluation of recombinant factor IX. , 1998, Seminars in hematology.
[6] B. Nielsen,et al. Recombinant Factor IX , 1997, Thrombosis and Haemostasis.
[7] J. Katz,et al. Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Journal of pediatric hematology/oncology.
[8] N. Key,et al. Factor IX inhibitors and anaphylaxis in haemophilia B , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] M. Ragni,et al. Parvovirus B19 infection in patients with hemophilia , 1996, Transfusion.
[10] B. Furie,et al. A practical guide to the evaluation and treatment of hemophilia. , 1994, Blood.
[11] S. Emerson,et al. Transmission of Hepatitis A to Patients with Hemophilia by Factor VIII Concentrates Treated with Organic Solvent and Detergent To Inactivate Viruses , 1994, Annals of Internal Medicine.
[12] M. Morfini,et al. The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX , 1991, Thrombosis and Haemostasis.
[13] J. Lusher,et al. Thrombogenicity associated with factor IX complex concentrates. , 1991, Seminars in hematology.
[14] U. Delvos,et al. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study. , 1991, Thrombosis research.
[15] D. Brettler,et al. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. , 1990, Blood.
[16] S. Cinotti,et al. Single‐dose pharmacokinetics of Factor IX evaluated by model‐independent methods , 1987, European journal of haematology.
[17] L. Kingsley,et al. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B , 1987 .
[18] M. Ragni,et al. Immune hemolysis by isohemagglutinins in factor IX concentrates , 1987, Transfusion.
[19] L. Kingsley,et al. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B. , 1987, Blood.
[20] B. Furie,et al. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. , 1986, The Journal of biological chemistry.
[21] K. Kurachi,et al. Isolation and characterization of a cDNA coding for human factor IX. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Rees,et al. Molecular cloning of the gene for human anti-haemophilic factor IX , 1982, Nature.
[23] K. Bauer,et al. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. , 1982, Blood.
[24] D. Green,et al. A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.